

DIALOG

NOTE:

No A-document published by EPO
 LANGUAGE (Publication,Procedural,Application): English; English; English
 FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200011	919
CLAIMS B	(German)	200011	923
CLAIMS B	(French)	200011	1086
SPEC B	(English)	200011	5561
Total word count - document A			0
Total word count - document B			8489
Total word count - documents A + B			8489

33/3,AB/54 (Item 19 from file: 654)
 DIALOG(R)File 654:US Pat.Full.
 (c) format only 2001 The Dialog Corp. All rts. reserv.

03131108

Utility

METHODS AND COMPOSITIONS COMPRISING DNA DAMAGING AGENTS AND P53

PATENT NO.: 6,069,134
 ISSUED: May 30, 2000 (20000530)
 INVENTOR(s): Roth, Jack A., Houston, TX (Texas), US (United States of America)
 Fujiwara, Toshiyoshi, Okayama, JP (Japan)
 Grimm, Elizabeth A., Houston, TX (Texas), US (United States of America)
 Mukhopadhyay, Tapas, Houston, TX (Texas), US (United States of America)
 Zhang, Wei-Wei, Houston, TX (Texas), US (United States of America)
 Owen-Schaub, Laurie B., Houston, TX (Texas), US (United States of America)
 ASSIGNEE(s): Board of Regents, The University of Texas System, (A U.S. Company or Corporation), US (United States of America)
 [Assignee Code(s): 83960]
 APPL. NO.: 8-953,290
 FILED: October 17, 1997 (19971017)

This is a divisional application of Ser. No. 08-233,002 filed Apr. 25, 1994, now U.S. Pat. No. 5,747,469, issued May 5, 1998.

The government owns rights in the present invention pursuant to NIH grants RO1 CA 45187 and CA 16672, and Training Grants CA 09611 and CA 45225.

FULL TEXT: 2426 lines

ABSTRACT

The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of

DIALOG

the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

33/3,AB/58 (Item 23 from file: 654)
DIALOG(R) File 654:US Pat.Full.
(c) format only 2001 The Dialog Corp. All rts. reserv.

03073078

Utility

METHODS AND COMPOSITIONS FOR SCREENING FOR OR MODULATING A TUMOR ASSOCIATED ANTIGEN

[Screening for bladder cancer by detecting the presences of a tumor-associated human complement factor H antigen in a biological sample by hybridization and amplification by polymerase chain reaction]

PATENT NO.: 6,017,703
ISSUED: January 25, 2000 (20000125)
INVENTOR(s): Kinders, Robert J., Woodinville, WA (Washington), US (United States of America)
Enfield, David L., Bothell, WA (Washington), US (United States of America)
Hass, G. Michael, Issaquah, WA (Washington), US (United States of America)
ASSIGNEE(s): Bard Diagnostic Sciences, Inc , (A U.S. Company or Corporation), Redmond, WA (Washington), US (United States of America)
[Assignee Code(s): 39396]
APPL. NO.: 8-824,692
FILED: April 08, 1997 (19970408)

This application claims the benefit of U.S. Provisional Applications 60-015,083, filed Apr. 9, 1996 and 60-038,614, filed Mar. 6, 1997.

FULL TEXT: 2889 lines

ABSTRACT

Methods of screening for or treating cancer are disclosed. The screening methods are based on the detection of an antigen, or a nucleic acid molecule encoding the antigen, found by the present invention to be associated with the presence of cancer. Preferred embodiments of the methods include detection of the antigen based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding the antigen based on nucleic acid amplification.

33/3,AB/63 (Item 28 from file: 654)
DIALOG(R) File 654:US Pat.Full.
(c) format only 2001 The Dialog Corp. All rts. reserv.

03008424

Utility

METHODS OF TREATING COLON CANCER UTILIZING TUMOR-SPECIFIC ANTIBODIES

7, March 27, 2001, 15:48

DIALOG

[Administering conjugate of antibody and anti-cancer drug, where in antibody is specific for A33 antigen for promoting colon or **gastric cancer** regression]

PATENT NO.: 5,958,412
ISSUED: September 28, 1999 (19990928)
INVENTOR(s): Welt, Sydney, New York, NY (New York), US (United States of America)
Old, Lloyd J., New York, NY (New York), US (United States of America)
Barendswaard, Elsje, New York, NY (New York), US (United States of America)
Montalto, Nicholas J., New York, NY (New York), US (United States of America)
Gure, Ali Osmay, New York, NY (New York), US (United States of America)
ASSIGNEE(s): Ludwig Institute For Cancer Research, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 28349]
APPL. NO.: 8-869,102
FILED: June 04, 1997 (19970604)

This application is a divisional of U.S. patent application Ser. No. 08-449,911, filed May 25, 1995 now U.S. Pat. No. 5,851,526, which is a Continuation-In-Part of U.S. patent application Ser. No. 08-020,223 filed Feb. 16, 1993, now U.S. Pat. No. 5,431,897; which is a Continuation Application of U.S. patent application Ser. No. 07-673,153 filed on Mar. 18, 1991, abandoned; which is a Continuation Application of U.S. patent application Ser. No. 07-327,765 filed Mar. 23, 1989, abandoned; which is a Continuation-In-Part Application of U.S. patent application Ser. No. 07-118,411 filed Nov. 6, 1987, abandoned; which is a Continuation Application of U.S. patent application Ser. No. 06-724,991 filed Apr. 19, 1985, abandoned.

FULL TEXT: 1083 lines

ABSTRACT

This invention relates to methods of reducing the effects of colon cancer tumors. Various agents are conjugated to **monoclonal antibodies** which are specific for colon cancer cells. The conjugates are administered to patients having colon cancer such that the effects of the cancer are reduced.

33/3,AB/72 (Item 37 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2001 The Dialog Corp. All rts. reserv.

02910162

Utility

METHOD OF TREATING ULCERATIVE COLITIS WITH A **MONOCLONAL ANTIBODY**

[Administering antibody which binds to colonic antigen associated with ulcerative colitis]

PATENT NO.: 5,869,048
ISSUED: February 09, 1999 (19990209)
INVENTOR(s): Das, Kiron M., Martinsville, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): University of Medicine & Dentistry, (A U.S. Company or

8, March 27, 2001, 15:48

DIALOG

Corporation), Newark, NJ (New Jersey), US (United States of America)

[Assignee Code(s): 8046]

APPL. NO.: 8-630,541

FILED: April 10, 1996 (19960410)

This application is a continuation-in-part of parent application Ser. No. 08-437,474, filed May 9, 1995, now abandoned.

FULL TEXT: 754 lines

ABSTRACT

The present invention pertains to a method for treating ulcerative colitis in a human which comprises orally or rectally administering to the human a therapeutically effective amount of an antibody which binds to a colonic antigen associated with ulcerative colitis. In another embodiment, the present invention pertains to a method for treating ulcerative colitis in a human which comprises the steps of (a) obtaining from a human a colon epithelial cell extract containing a colonic antigen associated with ulcerative colitis; (b) purifying the colonic antigen until the antigen is substantially homogeneous; (c) developing an antibody which binds to the colonic antigen; (d) orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of the antibody to bind to the colonic antigen associated with ulcerative colitis. In yet another embodiment, the present invention pertains to a method for vaccinating a human against ulcerative colitis which comprises orally administering to the human a therapeutically effective amount of a colonic antigen associated with ulcerative colitis.

33/3,AB/74 (Item 39 from file: 654)

DIALOG(R) File 654:US Pat.Full.

(c) format only 2001 The Dialog Corp. All rts. reserv.

02901614

Utility

COLON SPECIFIC GENE AND PROTEIN

[Utilizing polynucleotides or polypeptides as a diagnostic marker for colon cancer]

PATENT NO.: 5,861,494

ISSUED: January 19, 1999 (19990119)

INVENTOR(s): Soppet, Daniel R., Centreville, VA (Virginia), US (United States of America)

Li, Yi, Gaithersburg, MD (Maryland), US (United States of America)

Dillon, Patrick J., Gaithersburg, MD (Maryland), US (United States of America)

ASSIGNEE(s): Human Genome Sciences, Inc , (A U.S. Company or Corporation), Rockville, MD (Maryland), US (United States of America)

[Assignee Code(s): 38350]

APPL. NO.: 8-468,413

FILED: June 06, 1995 (19950606)

FULL TEXT: 1543 lines

ABSTRACT

Human colon specific gene polypeptides and DNA (RNA) encoding such

DIALOG

polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides or polypeptides as a diagnostic marker for colon cancer and as an agent to determine if colon cancer has metastasized. Also disclosed are antibodies specific to the colon specific gene polypeptides which may be used to target cancer cells and be used as part of a colon cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are also disclosed.

33/3,AB/81 (Item 46 from file: 654)

DIALOG(R) File 654:US Pat.Full.

(c) format only 2001 The Dialog Corp. All rts. reserv.

02764644

Utility

COLON SPECIFIC GENES AND PROTEINS

[Isolated polynucleotide; cancer diagnosis]

PATENT NO.: 5,733,748

ISSUED: March 31, 1998 (19980331)

INVENTOR(s): Yu, Guo-Liang, Darnestown, MD (Maryland), US (United States of America)

Rosen, Craig, Laytonsville, MD (Maryland), US (United States of America)

ASSIGNEE(s): Human Genome Sciences, Inc , (A U.S. Company or Corporation), Rockville, MD (Maryland), US (United States of America)

[Assignee Code(s): 38350]

APPL. NO.: 8-469,667

FILED: June 06, 1995 (19950606)

FULL TEXT: 2547 lines

ABSTRACT

Human colon specific gene polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides or polypeptides as a diagnostic marker for colon cancer and as an agent to determine if colon cancer has metastasized. Also disclosed are antibodies specific to the colon specific gene polypeptides which may be used to target cancer cells and be used as part of a colon cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are disclosed.

?

DIALOG

16/3,AB/3 (Item 1 from file: 434)
 DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
 (c) 1998 Inst for Sci Info. All rts. reserv.

08908362 Genuine Article#: P3197 Number of References: 21
**Title: ENZYME-LINKED IMMUNOSORBENT ASSAYS FOR SERUM PEPSINOGEN-I AND
 PEPSINOGEN-II USING MONOCLONAL- ANTIBODIES - WITH DATA ON
 PEPTIC-ULCER AND GASTRIC-CANCER**
 Author(s): HUANG SC; MIKI K; FURIHATA C; ICHINOSE M; SHIMIZU A; OKA H
 Corporate Source: UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,HONGO 7-3-1,BUNKYO
 KU/TOKYO 113//JAPAN/; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL/TOKYO
 113//JAPAN/
 Journal: CLINICA CHIMICA ACTA, 1988, V175, N1, P37-50
 Language: ENGLISH Document Type: ARTICLE

16/3,AB/4 (Item 1 from file: 348)
 DIALOG(R)File 348:EUROPEAN PATENTS
 (c) 2001 European Patent Office. All rts. reserv.

00192849
**-i (IN VITRO) DETECTION OF GASTROINTESTINAL CANCER.
 IN VITRO-NACHWEIS VON GASTROINTESTINALEM KREBS.
 DETECTION -i (IN VITRO) DU CANCER GASTROINTESTINAL.**
 PATENT ASSIGNEE:
 MUCAN DIAGNOSTICS PTY. LTD., (728670), 20th Floor, 500 Bourke Street,
 Melbourne, VIC 3000, (AU), (applicant designated states:
 AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
 INVENTOR:
 LINNANE, Anthony, William, 23/25 Canterbury Road, Camberwell, VIC 3124,
 (AU)
 LEGAL REPRESENTATIVE:
 Collier, Jeremy Austin Grey et al (29481), J.A.Kemp & Co. 14, South
 Square Gray's Inn, London WC1R 5EU, (GB)
 PATENT (CC, No, Kind, Date): EP 190159 A1 860813 (Basic)
 EP 190159 A1 880921
 EP 190159 B1 920909
 WO 8600414 860116
 APPLICATION (CC, No, Date): EP 85902944 850621; WO 85AU136 850621
 PRIORITY (CC, No, Date): AU 845672 840625
 DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
 INTERNATIONAL PATENT CLASS: G01N-033/68; G01N-033/53; G01N-033/577;
 NOTE:
 No A-document published by EPO
 LANGUAGE (Publication,Procedural,Application): English; English; English
 FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	532
CLAIMS B	(German)	EPBBF1	509
CLAIMS B	(French)	EPBBF1	620
SPEC B	(English)	EPBBF1	6947
Total word count - document A			0
Total word count - document B			8608
Total word count - documents A + B			8608

16/3,AB/5 (Item 1 from file: 349)
 DIALOG(R)File 349:PCT Fulltext
 (c) 2001 WIPO/MicroPat. All rts. reserv.

09/50,515
DIALOG

Set	Items	Description
S1	1049083	IMMUNOASSAY OR IMMUNOSORBENT OR ELISA OR EIA OR RIA OR RAD- IOIMMUNOASSAY OR CHEMILUMINESCEN?
S2	950	GASTRIC (W) INTESTINAL (W) METAPLASIA
S3	832017	MONOCLONAL (W) ANTIBOD?
S4	18505	DAS (W) 1
S5	6296	COLON (S) EPITHELIAL (S) PROTEIN? ?
S6	330144	IMMUNOPEROXIDASE OR PEROXIDASE OR DIAMINOBENZIDINE
S7	77371	AVIDIN OR STREPTAVIDIN
S8	108077	BIOTIN
S9	25756	HEMATOXYLIN
S10	555948	HISTOCHEMICAL OR HISTOLOGICAL OR HISTOIMMUNO?
S11	846060	TRYPSIN? OR ALDEHYDE? ?
S12	2455653	ALCOHOL OR METHANOL OR ETHANOL OR PROPANOL
S13	194624	XYLENE
S14	32968	EOSIN
S15	9	S1 AND S2 AND S3
S16	7	RD (unique items)
S17	70987	GASTRIC (W) (CANCER OR METAPLASIA)
S18	3199	S3 AND S17
S19	14709	INTESTIN? (W) (CANCER OR METAPLASIA)
S20	82114	S2 OR S17 OR S19
S21	1115	S1 AND S20 AND S3
S22	1115	S21 AND S3
S23	1	S4 AND S22
S24	10	S20 AND S4
S25	5	RD (unique items)
S26	97	S3 AND S4
S27	88	S26 NOT S24
S28	84	RD (unique items)
S29	77	S4/TI
S30	61	RD (unique items)
S31	1115	S1 AND S20 AND S3
S32	99	S31 AND S5
S33	97	RD (unique items)
S34	0	GASTRIC (W) INTESTINAL (W) METAPLASIA (W) (PROTEIN OR ANTIGEN)
S35	950	GASTRIC (W) INTESTINAL (W) METAPLASIA
S36	1588584	S1 OR S10
S37	950	S35 AND S35
S38	110	S35 AND S36
S39	53	S3 AND S35
S40	16	S38 AND S39
S41	10	RD (unique items)
S42	52477	IMMUNOPEROXIDASE
S43	373657	S6 OR S42
S44	17783	S10 AND S43
S45	2	S35 AND S44
S46	1263	S20 AND S43
S47	452	S46 AND S7 AND S8
S48	263	S47 AND S11
S49	238	S48 AND S12
S50	8	S49 AND S13 AND S14
S51	225	S49 AND STAIN?
S52	1759	E1-E12
S53	454	E13-E24
S54	130	AU="DAS K.M."
S55	383	AU="DAS KIRON" OR AU="DAS KIRON M" OR AU="DAS KIRON MOY" OR AU="DAS KM"
S56	2720	S52 OR S53 OR S54 OR S55
S57	212	S3 AND S56

DIALOG

60/3,AB/1 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10319393 20158159

Use of a novel monoclonal antibody in diagnosis of Barrett's esophagus.

Griffel LH; Amenta PS; Das KM
Department of Medicine, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA.
Digestive diseases and sciences (UNITED STATES) Jan 2000, 45 (1) p40-8
, ISSN 0163-2116 Journal Code: EAD
Contract/Grant No.: RO1 DK 44314, DK, NIDDK
Languages: ENGLISH
Document type: JOURNAL ARTICLE

A novel **monoclonal antibody** (MabDAS-1), that specifically reacts with colonic but not small intestinal epithelium, recognizes specialized columnar epithelium (SCE) in the esophagus. The frequency of its reactivity in biopsy specimens of patients with endoscopically suspected Barrett's Esophagus (BE) is examined. Fifty-two biopsy specimens of the distal esophagus from 38 patients were tested by immunoperoxidase method using MabDAS-1. Fifty-four samples of cardia-type mucosa biopsied from the stomach were used as controls. Results were compared with histology and Alcian blue/high iron diamine (AB/HID). Of the 52 specimens, 29 had glandular epithelium and the rest had only squamous epithelium. Ten were diagnosed to have SCE by histology. All 10 samples reacted with MabDAS-1 and with Alcian blue. Of the remaining 19 specimens, five also reacted with MabDAS-1. None of the squamous epithelium and cardia specimens reacted with MabDAS-1. MabDAS-1 may detect **intestinal metaplasia** of the esophagus of colonic phenotype in the absence of histological evidence of SCE.

60/3,AB/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09930408 99264862

Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin.

Murphy DP; Pantuck AJ; Amenta PS; Das KM ; Cummings KB; Keeney GL; Weiss RE

Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

Journal of urology (UNITED STATES) Jun 1999, 161 (6) p1881-4, ISSN 0022-5347 Journal Code: KC7

Contract/Grant No.: RO1 DK47673, DK, NIDDK

Languages: ENGLISH

Document type: JOURNAL ARTICLE

PURPOSE: Urethral adenocarcinoma is a rare malignancy whose origin remains controversial. The **monoclonal antibody** mAbDas1 (formerly 7E12H12) was developed against a unique colonic epithelial epitope and is reactive in areas of **intestinal metaplasia**. Recently the antibody was shown to react in cystitis glandularis as well as adenocarcinoma of the bladder, suggesting that cystitis glandularis may be the precursor of bladder adenocarcinoma. We examined urethral adenocarcinomas and benign urethral specimens using mAbDas1 to determine whether it could provide insight into their histogenesis. MATERIALS AND METHODS: Archival tissue from 12 cases of primary female urethral adenocarcinoma and urethral specimens of inflamed urethral mucosa, urethritis glandularis and transitional cell carcinoma was studied. Immunohistochemical analysis of

DIALOG

51/3,AB/7 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00341845

Anti-human gastric cancer monoclonal antibody.
Monoklonaler Antikörper gegen menschlichen Magenkrebs.
Anticorps monoclonal contre le cancer gastrique humain.
PATENT ASSIGNEE:

KYOWA HAKKO KOGYO CO., LTD., (229062), 6-1, Ohte-Machi 1-chome,
Chiyoda-ku Tokyo-to, (JP), (applicant designated states: DE;FR;GB)

INVENTOR:

Yoshida, Hajime, 9-18, Isobe, Sagamihara-shi Kanagawa, (JP)
Furuya, Akiko, I 15-405, 1210, Kisomachi, Machida-shi Tokyo, (JP)

LEGAL REPRESENTATIVE:

Kinzebach, Werner, Dr. et al (6468), Patentanwälte Reitstotter, Kinzebach
und Partner Sternwartstrasse 4 Postfach 86 06 49, D-8000 München 86,
(DE)

PATENT (CC, No, Kind, Date): EP 339633 A2 891102 (Basic)
EP 339633 A3 900530

APPLICATION (CC, No, Date): EP 89107623 890427;

PRIORITY (CC, No, Date): JP 88105597 880428

DESIGNATED STATES: DE; FR; GB

INTERNATIONAL PATENT CLASS: C07K-015/00; C12P-021/00; C12N-005/00;
C12N-015/00; G01N-033/574; G01N-033/577; C12P-021/00; C12R-001/91

ABSTRACT EP 339633 A2

An anti-human **gastric cancer** monoclonal antibody which belongs to the class IgM, reacts with human **gastric cancer** tissues but not with human normal tissues, recognizes unsialylated glycoproteins as antigens and shows no cross reactivity to carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP), a pathologic diagnosis of **gastric cancer** using said monoclonal antibody and a serodiagnosis or monitoring of **gastric cancer**, hepatic cancer, gallbladder carcinoma and/or biliary duct carcinoma using said monoclonal antibody.

ABSTRACT WORD COUNT: 75

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	227
SPEC A	(English)	EPABF1	4754
Total word count - document A			4981
Total word count - document B			0
Total word count - documents A + B			4981

51/3,AB/8 (Item 8 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00273582

Anti-human cancer monoclonal antibodies.
Monoklonale Antikörper gegen menschlichen Krebs.
Anticorps monoclonaux contre le cancer humain.
PATENT ASSIGNEE:

KYOWA HAKKO KOGYO CO., LTD., (229064), 6-1, Ohte-Machi 1-chome,
Chiyoda-ku Tokyo, (JP), (applicant designated states: DE;FR;GB)

INVENTOR:

Yoshida, Hajime, c/o Patent Department Kyowa Hakko Kogyo Co. Ltd., 6-1

41/3,AB/2 (Item 2 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2000 Dialog Corporation. All rts. reserv.

07361255 91236186

Reactivity of monoclonal antibody (mAb) GD9 with a cytoplasmic antigen preserved in formalin-fixed, paraffin-embedded gastrointestinal tumors.

D'Errico A; Facchini A; Meliconi R; Grigioni FW; Ferrone S
 Institute of Anatomia Patologica, University of Bologna, Italy.
 Hybridoma (UNITED STATES) Feb 1991, 10 (1) p113-9, ISSN 0272-457X
 Journal Code: GFS

Contract/Grant No.: CA 37959, CA, NCI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

In order to develop **monoclonal antibodies** to tumor associated antigens which are preserved in formalin-fixed, paraffin-embedded tissues, BALB/c mice were immunized with a formalin-fixed paraffin-embedded melanoma lesion. One of the resulting **monoclonal antibodies**, **monoclonal antibody** (mAb) GD9, stained formalin-fixed, paraffin-embedded melanoma lesions. When tested with a large panel of normal tissues from adults and from two fetuses of 4 and 16 week gestation and of benign and malignant tumors of different embryological origin, the mAb GD9 stained normal small bowel mucosa, areas of **gastric intestinal metaplasia**, the 6 pancreatic carcinoid tumors tested and a high percentage of gastrointestinal tumors. In the latter group, the reactivity with well differentiated tumors was higher than with poorly differentiated ones. Furthermore, the percentage of malignant cells stained by mAb GD9 in differentiated tumors was higher than in poorly differentiated ones. In the latter, the staining was diffuse and granular, while in the former, the staining was located in the cytoplasm close to the glandular lumen. The reactivity of mAb GD9 with colon carcinomas did not correlate with the Duke's staging and with the clinical course of the disease. The results of the immunohistochemical staining of normal tissues and benign and malignant lesions suggest that the specificity of mAb GD9 is different from that of previously described **monoclonal antibodies** which recognize tumor associated antigens expressed by tumors of the gastrointestinal tract.

41/3,AB/4 (Item 1 from file: 73)
 DIALOG(R) File 73:EMBASE
 (c) 2001 Elsevier Science B.V. All rts. reserv.

05965342 EMBASE No: 1994374929

The Thomsen-Friedenreich antigen-related carbohydrate antigens in human gastric intestinal metaplasia and cancer

Sotozono M.-A.; Okada Y.; Tsuji T.

Dept. of Nutritional Science, Faculty of Health/Welfare Science, Okayama Prefectural U., 111 Kuboki, Soja, Okayama 719-11 Japan

Journal of Histochemistry and Cytochemistry (J. HISTOCHEM. CYTOCHEM.) (United States) 1994, 42/12 (1575-1584)

CODEN: JHCYA ISSN: 0022-1554

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The Thomsen-Friedenreich antigen (T) is the core disaccharide of O-glycosylated complex carbohydrates and is presumed to be a cancer-associated carbohydrate antigen. However, we recently found that the expression of alpha-T and alpha-2 fucosyl alpha-T in the gastric surface epithelia was regulated allogeneically. In the present study we addressed

DIALOG

33/3,AB/1 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

05251996 87204149

Development of a monoclonal antibody specifically reactive to gastrointestinal goblet cells.

Vecchi M; Sakamaki S; Diamond B; Novikoff AB; Novikoff PM; Das KM
Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) May 1987, 84 (10) p3425-9, ISSN 0027-8424
Journal Code: PV3

Contract/Grant No.: AM-26403, AM, NIADDK; AM-32371, AM, NIADDK; CA-06576, CA, NCI; +

Languages: ENGLISH

Document type: JOURNAL ARTICLE

A mouse **monoclonal antibody** (7E6A5) of IgG isotype, reacting specifically with mucin-producing goblet cells of the human gastrointestinal tract, has been developed. 7E6A5 reacts by an **ELISA** with colonic **protein** eluted from a DEAE column. A screening by immunoperoxidase assay of 76 specimens from 19 different human tissues showed that the immunoreactivity of 7E6A5 was confined exclusively in the globules of goblet cells in the **colon**, the appendix, and the small intestine. Nongoblet small and large intestinal **epithelial** cells did not react. Immunoelectron microscopy demonstrated the reactivity with mucin droplets in a homogeneous granular pattern inside the globules of goblet cells. Mucus-secreting cells from remaining parts of the gastrointestinal tract and other mucus-secreting organs such as respiratory, genitourinary tracts, salivary and mammary glands did not show any reactivity to 7E6A5. These findings indicate that the antigen recognized by 7E6A5 is shared by the goblet cells of both the small and large intestines and is unique to them. The **monoclonal antibody** may be useful in the study of function of mucus-secreting goblet cells and may represent an important tool in the evaluation of diseases such as ulcerative colitis, **colon** cancer, and **intestinal metaplasia** in gastric mucosa that are associated with quantitative changes in goblet cell numbers or with qualitative differences in mucin secretion.

33/3,AB/17 (Item 14 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00743044

**HUMAN CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER CHEZ L'HOMME**

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)
RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,
US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055350 A1 20000921 (WO 0055350)
Application: WO 2000US5882 20000308 (PCT/WO US0005882)

DIALOG

30/3,AB/7 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12919343 BIOSIS NO.: 200100126492

Expression of the colonic epithelial antigen Das- 1 in primary lung adenocarcinomas: Intestinal differentiation or oncofetal reactivation?

AUTHOR: Deshpande C G(a); Shah R N(a); Papreddy K(a); Yeldandi A V(a);
Badve S(a)

AUTHOR ADDRESS: (a)Northwestern University, Chicago, IL**USA

JOURNAL: Laboratory Investigation 81 (1):p218A January, 2001

MEDIUM: print

CONFERENCE/MEETING: Annual Meeting of the United States and Canadian
Academy of Pathology Atlanta, Georgia, USA March 03-09, 2001

ISSN: 0023-6837

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English
2001

30/3,AB/9 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11745704 BIOSIS NO.: 199800526400

Expression of a unique epithelial antigen recognized by mAb DAS- 1 in intact fetal human liver and isolated fetal liver cells.

AUTHOR: Badve S(a); Logdberg L(a); Slehria S(a); Sigal S; Das K M; Gupta S
(a)

AUTHOR ADDRESS: (a)Albert Einstein Coll. Med., New York, NY**USA

JOURNAL: Hepatology 28 (4 PART 2):p523A Oct., 1998

CONFERENCE/MEETING: Biennial Scientific Meeting of the International
Association for the Study of the Liver and the 49th Annual Meeting and
Postgraduate Courses of the American Association for the Study of Liver
Diseases Chicago, Illinois, USA November 4-10, 1998

SPONSOR: International Association for the Study of the Liver

ISSN: 0270-9139

RECORD TYPE: Citation

LANGUAGE: English

1998

30/3,AB/10 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11419772 BIOSIS NO.: 199800201104

The anti-colonic epithelial MAb, mAb Das- 1, reacts with hepatoblasts in the fetal human liver and cells in additional fetal tissues.

AUTHOR: Badve S; Logdberg L; Slehria S; Sigal S; Das K M; Gupta S

AUTHOR ADDRESS: Albert Einstein Coll. Med., Mount Sinai Sch. Med., New
York, NY**USA

JOURNAL: FASEB Journal 12 (4):pA470 March 17, 1998

CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists
on Experimental Biology 98, Part 1 San Francisco, California, USA April
18-22, 1998

SPONSOR: Federation of American Societies for Experimental Biology

ISSN: 0892-6638

RECORD TYPE: Citation

LANGUAGE: English

DIALOG

28/3,AB/6 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11419772 BIOSIS NO.: 199800201104
The anti-colonic epithelial MAb, mAb Das- 1, reacts with hepatoblasts in the fetal human liver and cells in additional fetal tissues.
AUTHOR: Badve S; Logdberg L; Slehria S; Sigal S; Das K M; Gupta S
AUTHOR ADDRESS: Albert Einstein Coll. Med., Mount Sinai Sch. Med., New York, NY**USA
JOURNAL: FASEB Journal 12 (4):pA470 March 17, 1998
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists on Experimental Biology 98, Part 1 San Francisco, California, USA April 18-22, 1998
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English
1998

28/3,AB/10 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00835164
Method of producing human monoclonal antibodies and their use
Verfahren zur Herstellung von menschlichen monoklonalen Antikörpern und deren Verwendung
Procede de preparation d'anticorps monoclonaux humains et leur utilisation
PATENT ASSIGNEE:
GSF-Forschungszentrum für Umwelt und Gesundheit, GmbH, (210872),
Ingolstadter Landstrasse 1, D-85764 Oberschleissheim, (DE), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;NL;SE)
INVENTOR:
Bornkamm, Georg Wilhelm, Prof., Otilostrasse 6a, 81243 München, (DE)
Eick, Dirk, Priv. Doz. Dr., Neue Gautinger Str. 18, 82110 Germering, (DE)
Kempkes, Bettina, Dr., 168 Gerryroad, Chestnut Hill, MA 02167, (US)
Jochner, Nicola Maria, Abelestr. 9, 85354 Freising, (DE)
LEGAL REPRESENTATIVE:
Behnisch, Werner, Dr. (77851), Reinhard-Skühra-Weise & Partner,
Patentanwalte, Postfach 44 01 51, 80750 München, (DE)
PATENT (CC, No, Kind, Date): EP 773228 A1 970514 (Basic)
APPLICATION (CC, No, Date): EP 96117361 961029;
PRIORITY (CC, No, Date): DE 19541844 951109
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: C07K-016/00; C07K-014/05; C07K-014/72;
C12N-015/86

ABSTRACT EP 773228 A1 (Translated)
Production of human **monoclonal antibodies** from human B cells
Production of human **monoclonal antibodies** comprises:
(a) immortalising human antibody-producing B cells with a modified Epstein-Barr virus (EBV);
(b) screening the immortalised B cells for specificity to a target antigen;
(c) isolating clones that produce the corresponding antibody, (culturing the clones), and
(d) recovering the antibodies from the culture supernatants.
The modified EBV has a nuclear antigen 2 (EBNA2) gene that can be

DIALOG

cells, antibodies directed to colon cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of colon cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

French Abstract

La presente invention concerne l'identification de polynucleotides lies au colon ou au cancer du colon et les polypeptides codes par ces polynucleotides appeles ici de facon collective <=antigenes du cancer du colon>=, et l'utilisation de ces antigenes du colon dans la detection des troubles du tube digestif, et plus particulierement de la presence du cancer du colon et de metastases du cancer du colon. Cette invention concerne des antigenes du cancer du colon, de meme que des vecteurs, des cellules hotes, des anticorps diriges contre ces antigenes du cancer du colon et des technique de recombinaison et de synthese permettant la production de ceux-ci. Cette invention concerne aussi des techniques diagnostiques permettant de detecter, traiter, prevenir et/ou de pronostiquer des pathologies liees au colon, notamment le cancer du colon, et des techniques therapeutiques permettant de traiter ces pathologies. Cette invention concerne encore des methodes de recherche permettant d'identifier des agonistes et des antagonistes des antigenes du cancer du colon de l'invention. Enfin cette invention traite de la facon d'inhiber la production et la fonction des polypeptides de l'invention.

?

DIALOG

[Assignee Code(s): 20266]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 25,
1994 (19940525)
APPL. NO.: 7-270,765
FILED: November 14, 1988 (19881114)
PRIORITY: PG5672, AU (Australia), June 25, 1984 (19840625)

This is a division of application Ser. No. 06-860,223, filed as PCT
AU85-00136 on Jan. 21, 1985, published as WO86-00414 on Jun. 16, 1986, now
U.S. Pat. No. 4,818,682.

FULL TEXT: 929 lines

ABSTRACT

This invention involves a kit or system for detecting SIMA and/or LIMA
antigens in a physiological fluid.
?

DIALOG

ASSIGNEE(s): Thomas Jefferson University, (A U.S. Company or Corporation),
Philadelphia, PA (Pennsylvania), US (United States of America)
[Assignee Code(s): 6943]
APPL. NO.: 9-193,997
FILED: November 17, 1998 (19981117)

CROSS REFERENCE TO RELATED PATENT APPLICATIONS

This Application is a continuation application of U.S. Ser. No. 08-467,920 filed Jun. 6, 1995, issued Oct. 5, 1999 as U.S. Pat. No. 5,962,220, which is a continuation in part application of U.S. Ser. No. 08-141,892 filed Oct. 26, 1993, issued May 21, 1996 as U.S. Pat. No. 5,518,888, which is herein incorporated by reference. This application is also related to U.S. Ser. No. 08-305,056 filed Sep. 13, 1994, issued Feb. 11, 1997 as U.S. Pat. No. 5,601,990, and PCT application Ser. No. PCT-US94-12232 filed Oct. 26, 1994, the disclosure of both of which are herein incorporated by reference.

FULL TEXT: 1812 lines

ABSTRACT

Conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed. Pharmaceutical compositions which comprise conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed including pharmaceutical compositions that have enteric formulations. Methods of treating an individual suspected of suffering from colorectal cancer and methods of preventing colorectal cancer are disclosed.

33/3,AB/2 (Item 1 from file: 348)
DIALOG(R) File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00616073

ACCEPTOR FOR FUCOSYLTRANSFERASE

AKZEPTOR FUR FUCOSYLTRANSFERASE

ACCEPTEUR DE FUCOSYLTRANSFERASE

PATENT ASSIGNEE:

HEALTH RESEARCH, INC., (522423), Roswell Park Division, 666 Elm Street,
Buffalo, NY 14263, (US), (Proprietor designated states: all)

INVENTOR:

MATTA, Khushi, L., 206 Exeter Road, Williamsville, NY 14221, (US)

CHANDRASEKARAN, E., V., 1635 Holly Avenue, Northbrook, IL 60062, (US)

JAIN, Rakesh, K., 454/34 Sukhdev Bhawan, Palbichla Ajmer-305001, (IN)

LEGAL REPRESENTATIVE:

Nyeng, Joergen et al (61191), c/o Hofman-Bang & Boutard, Lehmann & Ree

A/S, Hans Bekkevolds Alle 7, 2900 Hellerup, (DK)

PATENT (CC, No, Kind, Date): EP 648279 A1 950419 (Basic)

EP 648279 A1 970122

EP 648279 B1 000315

WO 9400596 940106

APPLICATION (CC, No, Date): EP 93916781 930628; WO 93US6097 930628

PRIORITY (CC, No, Date): US 905797 920629

DESIGNATED STATES: DE; DK; FR; GB; NL

INTERNATIONAL PATENT CLASS: C12Q-001/48; C12N-009/10; C07H-015/02;

A61K-031/70; C07H-015/203; C07H-003/06; C07H-015/18; C07H-013/04

5, March 27, 2001, 15:48

DIALOG

S58	204	S57 NOT PY>2000
S59	33	S58 AND S20
S60	14	RD (unique items)
?		

DIALOG

formalin fixed, paraffin embedded archival tissue was done using the **monoclonal antibody mAbDas1**. Tumors were also evaluated with a prostate specific antigen (PSA) polyclonal antibody as previous studies have noted PSA reactivity in these tumors. RESULTS: Of the 12 cases 9 were columnar/mucinous adenocarcinoma, 2 clear cell adenocarcinoma and 1 a cribriform pattern resembling adenocarcinoma of the prostate. All columnar/mucinous adenocarcinomas reacted positively (6 strongly and 3 focally) with the mAbDas1 antibody but did not react with the PSA antibody. The tumor with a cribriform pattern reacted strongly with PSA but did not react with mAbDas1. The 2 clear cell adenocarcinomas did not react with either antibody. The benign urethral specimens demonstrated strong reactivity to the mAbDas1 antibody in areas of urethritis glandularis but normal and inflamed urethral mucosa and transitional cell carcinoma did not react. CONCLUSIONS: Primary adenocarcinoma of the female urethra arises from more than 1 tissue of origin. Columnar/mucinous adenocarcinomas of the female urethra and urethritis glandularis demonstrate consistent reactivity with the mAbDas1 antibody, suggesting that these tumors arise from glandular metaplasia analogous to the potential histogenesis previously demonstrated in the bladder. PSA reactivity occurred in 1 tumor with a cribriform pattern and likely represents origin from Skene's glands. Clear cell adenocarcinomas did not react with either antibody, suggesting a third possible pathway in the development of this rare subset of adenocarcinomas.

60/3,AB/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09668859 98446060

The monoclonal antibody 7E12H12 can differentiate primary adenocarcinoma of the bladder and prostate.

Pantuck AJ; Murphy DP; Amenta PS; Das KM ; Cummings KB; Weiss RE
Division of Urology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

British journal of urology (ENGLAND) Sep 1998, 82 (3) p426-30, ISSN 0007-1331 Journal Code: B3K

Languages: ENGLISH

Document type: JOURNAL ARTICLE

OBJECTIVE: To determine if the **monoclonal antibody 7E12H12**, which reacts with a 40 kDa protein in normal human enterocytes and has been shown to be a marker for **intestinal metaplasia** and adenocarcinoma arising in the bladder, could assist in distinguishing prostatic, urachal and vesical adenocarcinoma, using a sensitive immunohistochemical assay. MATERIALS AND METHODS: Fifteen primary prostatic adenocarcinomas and five adenocarcinomas of the urinary bladder were selected for a retrospective evaluation. The **monoclonal antibody 7E12H12** (IgM isotype) was used in an immunoperoxidase assay to survey formalin-fixed, paraffin-embedded archival tissue specimens. RESULTS: All vesical adenocarcinomas reacted positively with the antibody, regardless of grade; none of the 15 prostatic specimens reacted positively in either the benign or malignant glandular epithelium. CONCLUSION: The **monoclonal antibody 7E12H12** can differentiate primary adenocarcinoma of the bladder from secondary adenocarcinoma arising in the prostate and may be a useful tool in diagnostic pathology.

60/3,AB/4 (Item 4 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09303907 97475063

Adenocarcinoma of the urachus and bladder expresses a unique colonic

DIALOG

Ohtemachi Itchome Chiyoda-ku Tokyo, (JP)
 Furuya, Akiko, c/o Patent Department Kyowa Hakko Kogyo Co. Ltd., 6-1
 Ohtemachi Itchome Chiyoda-ku Tokyo, (JP)

LEGAL REPRESENTATIVE:

Lambert, Hugh Richmond et al , D. YOUNG & CO. 10 Staple Inn, London, WC1V
 7RD, (GB)

PATENT (CC, No, Kind, Date): EP 272113 A2 880622 (Basic)
 EP 272113 A3 900307

APPLICATION (CC, No, Date): EP 87311102 871216;

PRIORITY (CC, No, Date): JP 86302410 861218

DESIGNATED STATES: DE; FR; GB

INTERNATIONAL PATENT CLASS: C12P-021/00; C07K-015/00; G01N-033/574;
 G01N-033/577;

ABSTRACT EP 272113 A2

Monoclonal antibodies are disclosed capable of specifically reacting
 with human colorectal cancer cells and non-reactive with normal
 colorectal cells, and useful in the diagnosis of human colorectal cancer.

ABSTRACT WORD COUNT: 32

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	622
SPEC A	(English)	EPABF1	4026
Total word count - document A			4648
Total word count - document B			0
Total word count - documents A + B			4648

51/3,AB/9 (Item 9 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00268813

Anti-human gastric cancer monoclonal antibody.

Monoklonale anti-menschliche Magenkrebs-Antikörper.

Anticorps monoclonal anti-cancer gastrique humain.

PATENT ASSIGNEE:

KYOWA HAKKO KOGYO CO., LTD., (229064), 6-1, Ohte-Machi Itchome,
 Chiyoda-ku Tokyo, (JP), (applicant designated states: DE;FR;GB)

INVENTOR:

Yoshida, Hajime Patent Department, Kyowa Hakko Kogyo Co.Ltd 6-1 Ohtemachi
 Itchome, Chiyoda-ku Tokyo, (JP)

Hanai, Nobuo Patent Department, Kyowa Hakko Kogyo Co.Ltd 6-1 Ohtemachi
 Itchome, Chiyoda-ku Tokyo, (JP)

Furuya, Akiko Patent Department, Kyowa Hakko Kogyo Co.Ltd 6-1 Ohtemachi
 Itchome, Chiyoda-ku Tokyo, (JP)

LEGAL REPRESENTATIVE:

Lambert, Hugh Richmond et al (32791), D. YOUNG & CO. 10 Staple Inn,
 London, WC1V 7RD, (GB)

PATENT (CC, No, Kind, Date): EP 253646 A2 880120 (Basic)
 EP 253646 A3 900131
 EP 253646 B1 930512

APPLICATION (CC, No, Date): EP 87306257 870715;

PRIORITY (CC, No, Date): JP 86166138 860715

DESIGNATED STATES: DE; FR; GB

INTERNATIONAL PATENT CLASS: C12P-021/00; C07K-015/00; C12N-005/00;
 C12N-015/00; G01N-033/577; G01N-033/574; C12P-021/00; C12R-001/91

DIALOG

their changes in gastric differentiation disorders. Expression of the T-related antigens was studied histochemically with **monoclonal antibody** MBrl and peanut agglutinin in 22 normal, 14 metaplastic, and 34 cancerous tissues. The sialylated antigens were detected after neuraminidase digestion. Gastric mucins were purified and examined to determine whether they were the carrier molecules of T. Expression of the normal antigens was decreased or not detected in about 80% of both disorders. Neosialylation of the T-related antigens was observed in the goblet cells of all metaplastic tissues. The absorptive cells did not express any T-related antigens. In gastric cancers, blocked synthesis, i.e., precursor accumulation or totally negative expression, was observed in ~66% and neosialylation in ~40%. The T-related antigens were carried by mucins. We conclude that blocked synthesis of the T-related antigens was found in a cancer-specific manner. Neosialylation was invariably associated with intestinal metaplasia and occasionally with cancer.

41/3,AB/5 (Item 1 from file: 434)

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08908362 Genuine Article#: P3197 Number of References: 21

Title: ENZYME-LINKED IMMUNOSORBENT ASSAYS FOR SERUM PEPSINOGEN-I AND PEPSINOGEN-II USING MONOCLONAL- ANTIBODIES - WITH DATA ON PEPTIC-ULCER AND GASTRIC-CANCER

Author(s): HUANG SC; MIKI K; FURIHATA C; ICHINOSE M; SHIMIZU A; OKA H
Corporate Source: UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,HONGO 7-3-1,BUNKYO KU/TOKYO 113//JAPAN//; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL/TOKYO 113//JAPAN/

Journal: CLINICA CHIMICA ACTA, 1988, V175, N1, P37-50

Language: ENGLISH Document Type: ARTICLE

41/3,AB/6 (Item 2 from file: 434)

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08605424 Genuine Article#: M0878 Number of References: 44

Title: WIDESPREAD EXPRESSION OF INTESTINAL MARKERS IN GASTRIC-CARCINOMA - A LIGHT AND ELECTRON-MICROSCOPIC STUDY USING BD-5 MONOCLONAL- ANTIBODY

Author(s): FIOCCA R; VILLANI L; TENTI P; CORNAGGIA M; FINZI G; CAPELLA C; PRAT M; BUSSOLATI G; SOLCIA E

Corporate Source: IRCCS POLICLIN SAN MATTED/PAVIA//ITALY//; MULTIZONAL HOSP/VARESE//ITALY//; UNIV PAVIA,DEPT HUMAN PATHOL/I-27100 PAVIA//ITALY//; UNIV TURIN,DEPT BIOMED SCI & ONCOL/I-10124 TURIN//ITALY/

Journal: JOURNAL OF CLINICAL PATHOLOGY, 1988, V41, N2, P178-187

Language: ENGLISH Document Type: ARTICLE

41/3,AB/7 (Item 1 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00192849

-i (IN VITRO) DETECTION OF GASTROINTESTINAL CANCER.

IN VITRO-NACHWEIS VON GASTROINTESTINALEM KREBS.

DETECTION -i (IN VITRO) DU CANCER GASTROINTESTINAL.

PATENT ASSIGNEE:

MUCAN DIAGNOSTICS PTY. LTD., (728670), 20th Floor, 500 Bourke Street,
Melbourne, VIC 3000, (AU), (applicant designated states:
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

DIALOG

1998
?

DIALOG

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 223528

English Abstract

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presence of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

Cette invention porte sur des polynucleotides recemment identifies et associes au cancer specifique d'un tissu, et sur les polypeptides codes par ces polynucleotides et connus collectivement sous le nom <=d'antigenes du cancer>=. L'invention porte egalement sur les sequences geniques completes associees et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigenes du cancer specifique d'un tissu dans la detection, la prevention et le traitement des pathologies specifiques d'un tissu telles que le cancer. Cette invention porte sur les antigenes du cancer, ainsi que sur les vecteurs, les cellules hotes, les anticorps diriges contre les antigenes du cancer et sur des procedes recombinants et synthetiques de production de ces anticorps. L'invention porte egalement sur des procedes de diagnostic permettant de diagnostiquer et traiter, prevenir et/ou etablir un pronostic de pathologies specifiques d'un tissu telles que le cancer, et sur des procedes therapeutiques visant a traiter ces pathologies. Cette invention porte en outre sur des procedes de recherche automatique visant a identifier des agonistes et des antagonistes des antigenes du cancer, et sur des procedes et/ou des compositions visant a inhiber la production et/ou la fonction des polypeptides de cette invention.

33/3,AB/24 (Item 21 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00627317

RECEPTOR FOR INTESTINAL TREFOIL FACTOR

RECEPTEUR DU FACTEUR DE TREFLE INTESTINAL

2, March 27, 2001, 15:48

DIALOG

switched on for the immortalisation step and switched off before the antibody recovery step.

TRANSLATED ABSTRACT WORD COUNT: 86

ABSTRACT EP 773228 A1

Production of human **monoclonal antibodies** from human B cells

Production of human **monoclonal antibodies** comprises:

(a) immortalising human antibody-producing B cells with a modified Epstein-Barr virus (EBV);

(b) screening the immortalised B cells for specificity to a target antigen;

(c) isolating clones that produce the corresponding antibody, (culturing the clones), and

(d) recovering the antibodies from the culture supernatants.

The modified EBV has a nuclear antigen 2 (EBNA2) gene that can be switched on for the immortalisation step and switched off before the antibody recovery step.

ABSTRACT EP 773228 A1

Erfindungsgemas wird ein Verfahren zur Herstellung von menschlichen monoklonalen Antikörpern mit folgenden Verfahrensschritten bereitgestellt:

a) Immortalisierung menschlicher, Antikörper produzierender B-Zellen mit einem Epstein-Barr-Virus oder einem Derivat hiervon,

b) Screening der immortalisierten B-Zellen auf Spezifität für das gewünschte Antigen und Isolation von Zellklonen, die entsprechende Antikörper produzieren,

c) Gewinnung der gewünschten Antikörper aus den Kulturüberständen; dieses Verfahren ist dadurch gekennzeichnet, dass

d) ein Epstein-Barr-Virus oder ein Derivat hiervon mit, in funktioneller Verbindung, einem konditionalen Epstein-Barr-Virus-Nuclear-Antigen 2-(EBNA2-)Gen oder einem Derivat hiervon verwendet wird, welches zur Immortalisierung zumindest teilweise angeschaltet wird, und

e) das EBNA2-Gen oder sein Derivat vor Gewinnung der Antikörper zumindest teilweise abgeschaltet wird.

ABSTRACT WORD COUNT: 104

LANGUAGE (Publication,Procedural,Application): German; German; German
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(German)	EPAB97	346
SPEC A	(German)	EPAB97	5217
Total word count - document A			5563
Total word count - document B			0
Total word count - documents A + B			5563

28/3,AB/28 (Item 21 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00391565

Conjugates for tumor localization and/or tumortherapy.

Konjugate zur Tumorklokalisation und/oder Tumorthherapie.

Conjugues pour la localisation et/ou la therapie des tumeurs.

PATENT ASSIGNEE:

Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts,
(577160), Im Neuenheimer Feld 280, W-6900 Heidelberg 1, (DE),
(applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

2, March 27, 2001, 15:31

DIALOG

00215439

IN VITRO DETECTION OF GASTROINTESTINAL CANCER
DETECTION IN VITRO DU CANCER GASTROINTESTINAL

Patent Applicant/Assignee:

MUCAN DIAGNOSTICS PTY LTD

LINNANE Anthony William

Inventor(s):

LINNANE Anthony William

Patent and Priority Information (Country, Number, Date):

Patent: WO 8600414 A1 19860116

Application: WO 85AU136 19850621 (PCT/WO AU8500136)

Priority Application: AU 845672 19840625

Designated States: AT AU BE BR CH DE DK FR GB IT JP KR LK LU NL NO SE US

Publication Language: English

Fulltext Word Count: 8329

English Abstract

An in vitro diagnostic method for detecting the presence in a patient of cancer cells or other cells producing mucin antigens comprises the step of testing a sample of a physiological fluid, particularly a sample of blood, blood serum or blood plasma, taken from the patient to detect the presence of small intestine mucin antigen (SIMA) and/or large intestine mucin antigen (LIMA) in the sample. An in vitro diagnostic kit is also disclosed.

Japanese Abstract

Procede de diagnostic in vitro pour detecter la presence chez un patient de cellules cancreuses ou d'autres cellules produisant des antigenes de mucine, comportant l'analyse d'un echantillon d'un fluide physiologique, en particulier un echantillon de sang, de serum sanguin ou de plasma sanguin, preleve chez le patient afin de detecter la presence dans l'echantillon d'un antigene mucine de l'intestin grele (SIMA) et/ou d'un antigene de mucine du gros intestin (LIMA). Est egalement decrit un kit de diagnostic in vitro.

16/3,AB/6 (Item 1 from file: 653)

DIALOG(R)File 653:US Patents Fulltext

(c) format only 2001 The Dialog Corp. All rts. reserv.

01756561

Utility

IN VITRO DETECTION OF GASTROINTESTINAL CANCER

[TESTING PHYSIOLOGICAL FLUID FOR SMALL OR LARGE INTTESTINE MUCIN ANTIGEN]

PATENT NO.: 4,818,682

ISSUED: April 04, 1989 (19890404)

INVENTOR(s): Linnane, Anthony W., Camberwell, AU (Australia)

ASSIGNEE(s): Mucan Diagnostics Pty Ltd , (A Non-U.S. Company or Corporation), Victoria, AU (Australia)

[Assignee Code(s): 20266]

EXTRA INFO: Assignment transaction [Reassigned], recorded May 25, 1994 (19940525)

APPL. NO.: 6-860,223

FILED: April 24, 1986 (19860424)

PRIORITY: PG5672, AU (Australia), June 25, 1984 (19840625)

PCT: PCT-AU85-00136 (WO 85AU136)

Section 371 Date: April 24, 1986 (19860424)

Section 102(e) Date: April 24, 1986 (19860424)

Filing Date: June 21, 1985 (19850621)

Publication Number: WO86-00414 (WO 86414)

2,March 27, 2001,15:12

DIALOG

epithelial epitope: an immunohistochemical study.

Pantuck AJ; Bancila E; Das KM ; Amenta PS; Cummings KB; Marks M; Weiss RE

Journal of urology (UNITED STATES) Nov 1997, 158 (5) p1722-7, ISSN 0022-5347 Journal Code: KC7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

PURPOSE: Primary adenocarcinoma of the bladder is a rare neoplasm whose histogenesis is poorly understood. Current data support the concept that adenocarcinoma of the bladder and urachus evolves from zones of **intestinal metaplasia** that become dysplastic and invasive. To address this hypothesis further we determined the immunoreactivity of benign and malignant epithelial tissue from the bladder and urachus with a **monoclonal antibody** that is reactive with colonic epithelium to evaluate the presence of a common reactive epitope. **MATERIALS AND METHODS:** The **monoclonal antibody** 7E12H12 (IgM isotype), developed against a colonic epithelial protein, was used in an immunoperoxidase assay to survey formalin fixed, paraffin embedded archival tissue specimens. A total of 26 specimens obtained by endoscopic biopsy or extirpative surgery, including benign and malignant bladder and urachal epithelial abnormalities, was chosen for retrospective evaluation. **RESULTS:** All adenocarcinoma reacted positively regardless of the histological variant, differentiation, or bladder or urachal origin. In contrast, transitional cell and squamous cell carcinomas were nonreactive. Also, the pattern of reactivity in tissues that contained benign epithelial proliferations suggested a stepwise transition with no reactivity in normal urothelium or Brunn's epithelial nests, rare staining of cystitis cystica, and uniformly positive reactivity in cystitis glandularis and frank colonic **intestinal metaplasia** of the bladder and urachus. **CONCLUSIONS:** The shared, aberrant phenotypic expression of a unique colonic epitope in benign epithelial metaplasia, and adenocarcinoma of the bladder and urachus suggests a common underlying pathway toward adenocarcinoma in cystic and urachal adenocarcinoma. The implications for diagnostic pathology are discussed.

60/3,AB/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

05251996 87204149

Development of a monoclonal antibody specifically reactive to gastrointestinal goblet cells.

Vecchi M; Sakamaki S; Diamond B; Novikoff AB; Novikoff PM; Das KM

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) May 1987, 84 (10) p3425-9, ISSN 0027-8424

Journal Code: PV3

Contract/Grant No.: AM-26403, AM, NIADDK; AM-32371, AM, NIADDK; CA-06576, CA, NCI; +

Languages: ENGLISH

Document type: JOURNAL ARTICLE

A mouse **monoclonal antibody** (7E6A5) of IgG isotype, reacting specifically with mucin-producing goblet cells of the human gastrointestinal tract, has been developed. 7E6A5 reacts by an ELISA with colonic protein eluted from a DEAE column. A screening by immunoperoxidase assay of 76 specimens from 19 different human tissues showed that the immunoreactivity of 7E6A5 was confined exclusively in the globules of goblet cells in the colon, the appendix, and the small intestine. Nongoblet small and large intestinal epithelial cells did not react. Immunoelectron microscopy demonstrated the reactivity with mucin droplets in a homogeneous granular pattern inside the globules of goblet cells. Mucus-secreting cells from remaining parts of the gastrointestinal tract and other

DIALOG

ABSTRACT EP 253646 A2

Anti-human **gastric cancer** monoclonal antibody.

Monoclonal antibodies are disclosed capable of reacting with human digestive system cancer, especially pancreatic cancer, and non-reactive with normal human stomach cells and tissue, the monoclonal antibodies recognizing sialylated glycoproteins and glycolipids as antigens, and being useful in the diagnosis of human digestive system, particularly pancreatic, cancer.

ABSTRACT WORD COUNT: 54

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	370
CLAIMS B	(German)	EPBBF1	326
CLAIMS B	(French)	EPBBF1	421
SPEC B	(English)	EPBBF1	4787
Total word count - document A			0
Total word count - document B			5904
Total word count - documents A + B			5904

51/3,AB/11 (Item 11 from file: 348)

DIALOG(R) File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00182987

Anti-human cancer monoclonal antibody.

Monoklonaler Antikörper gegen menschlichen Krebs.

Anticorps monoclonal contre le cancer humain.

PATENT ASSIGNEE:

WAKUNAGA SEIYAKU KABUSHIKI KAISHA, (559170), 1-39 Fukushima 3-chome
Fukushima-ku, Osaka-shi Osaka-fu, (JP), (applicant designated states:
DE;FR;GB)

INVENTOR:

Tahara, Eiichi, 1-6-9 Misuzugaokahigashi Itsukaichi-cho, Saeki-gun
Hiroshima, (JP)

Ochiai, Atsushi, 2-20-9 Hataga Aki-ku, Hiroshima-shi Hiroshima, (JP)
Yokozaki, Hiroshi, 2-26-14 Midori Minami-ku, Hiroshima-shi Hiroshima,
(JP)

Hozumi, Toyoharu Wakunaga Seiyaku K. K., The Central Research Lab. 1624
Shimokotachi, Koda-cho Takata-gun Hiroshima, (JP)

Kyo, Eikai Wakunaga Seiyaku K. K., The Central Research Lab. 1624
Shimokotachi, Koda-cho Takata-gun Hiroshima, (JP)

LEGAL REPRESENTATIVE:

Ford, Michael Frederick et al (30701), MEWBURN ELLIS & CO. 2/3 Cursitor
Street, London EC4A 1BQ, (GB)

PATENT (CC, No, Kind, Date): EP 180413 A2 860507 (Basic)
EP 180413 A3 881130
EP 180413 B1 911002

APPLICATION (CC, No, Date): EP 85307678 851024;

PRIORITY (CC, No, Date): JP 84223830 841026; JP 85198592 850910

DESIGNATED STATES: DE; FR; GB

INTERNATIONAL PATENT CLASS: C12N-005/20; C12P-021/08; A61K-039/395;
G01N-033/577;

ABSTRACT EP 180413 A2

Anti-human cancer monoclonal antibody.

A monoclonal antibody against human cancer, characterized in that the monoclonal antibody is produced by a hybridoma cell line obtained from the fusion of B-lymphocyte immunized with cells of human cancer origin

DIALOG

INVENTOR:

LINNANE, Anthony, William, 23/25 Canterbury Road, Camberwell, VIC 3124,
(AU)

LEGAL REPRESENTATIVE:

Collier, Jeremy Austin Grey et al (29481), J.A.Kemp & Co. 14, South
Square Gray's Inn, London WC1R 5EU, (GB)

PATENT (CC, No, Kind, Date): EP 190159 A1 860813 (Basic)

EP 190159 A1 880921

EP 190159 B1 920909

WO 8600414 860116

APPLICATION (CC, No, Date): EP 85902944 850621; WO 85AU136 850621

PRIORITY (CC, No, Date): AU 845672 840625

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: G01N-033/68; G01N-033/53; G01N-033/577;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	532
CLAIMS B	(German)	EPBBF1	509
CLAIMS B	(French)	EPBBF1	620
SPEC B	(English)	EPBBF1	6947
Total word count - document A			0
Total word count - document B			8608
Total word count - documents A + B			8608

41/3,AB/8 (Item 1 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00215439

IN VITRO DETECTION OF GASTROINTESTINAL CANCER

DETECTION IN VITRO DU CANCER GASTROINTESTINAL

Patent Applicant/Assignee:

MUCAN DIAGNOSTICS PTY LTD

LINNANE Anthony William

Inventor(s):

LINNANE Anthony William

Patent and Priority Information (Country, Number, Date):

Patent: WO 8600414 A1 19860116

Application: WO 85AU136 19850621 (PCT/WO AU8500136)

Priority Application: AU 845672 19840625

Designated States: AT AU BE BR CH DE DK FR GB IT JP KR LK LU NL NO SE US

Publication Language: English

Fulltext Word Count: 8329

English Abstract

An in vitro diagnostic method for detecting the presence in a patient of cancer cells or other cells producing mucin antigens comprises the step of testing a sample of a physiological fluid, particularly a sample of blood, blood serum or blood plasma, taken from the patient to detect the presence of small intestine mucin antigen (SIMA) and/or large intestine mucin antigen (LIMA) in the sample. An in vitro diagnostic kit is also disclosed.

Japanese Abstract

Procede de diagnostic in vitro pour detecter la presence chez un patient de cellules cancreuses ou d'autres cellules produisant des antigenes de mucine, comportant l'analyse d'un echantillon d'un fluide physiologique,

DIALOG

Patent Applicant/Assignee:

THE GENERAL HOSPITAL CORPORATION, THE GENERAL HOSPITAL CORPORATION , 55
Fruit Street, Boston, MA 02114 , US

Inventor(s):

PODOLSKY Daniel K, PODOLSKY, Daniel, K. , 67 Yarmouth Road, Wellesley
Hills, MA 02181 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9910377 A1 19990304

Application: WO 98US17552 19980825 (PCT/WO US9817552)

Priority Application: US 9756787 19970825

Designated States: CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
SE

Publication Language: English

Filing Language: English

Fulltext Word Count: 3523

English Abstract

A substantially pure intestinal trefoil factor receptor which is
obtainable from intestinal cells and has a molecular weight of about 50
to 60 kD or about 75 to 80 kD.

French Abstract

Recepteur du facteur de trefle intestinal sensiblement pur pouvant etre
obtenu a partir de cellules intestinales et dont le poids moleculaire est
compris entre environ 50 et 60 kD ou environ 75 et 80 kD.

33/3,AB/26 (Item 23 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00602197

CANCER MARKER

MARQUEUR UTILISE DANS LE DIAGNOSTIC DE CANCERS

Patent Applicant/Assignee:

UNIVERSITY OF LEICESTER, UNIVERSITY OF LEICESTER , University Road,
Leicester LE1 7RH , GB

Inventor(s):

SCHWAEBLE Wilhelm, SCHWAEBLE, Wilhelm , 13 Swithland Court, Woodhouse
Eves, Leicestershire LE12 8SJ , GB

Patent and Priority Information (Country, Number, Date):

Patent: WO 9848014 A1 19981029

Application: WO 98GB1184 19980423 (PCT/WO GB9801184)

Priority Application: GB 978190 19970423

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US
UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
ML MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 7486

English Abstract

The present invention concerns a cancer marker (protein), together with
the uses of the protein, immunogenic fragement or analogue thereof, or
binding agents specific against same in the treatment and diagnosis of
cancer, the use of same in the manufacture of medicaments, and test kits
and test methods for same. Also provided is a nucleotide sequence
encoding same.

DIALOG

INVENTOR:

Sinn, Hansjorg Dr., Ahornweg 10, W-6908 Wiesloch, (DE)
Schrenk, Hans-Hermann, Mittelgasse 3, W-6721 Zeiskam, (DE)
Maier-Borst, Wolfgang, Dr., Schlusselfweg 9, W-6901 Dossenheim, (DE)
Friedrich, Eckhard, Dr., In den Hofwiesen 6, W-6741 Ilbesheim, (DE)
Graschew, Georgi, Dr., Im Langgewann 5/29, W-6900 Heidelberg, (DE)
Wohrle, Dieter, Prof. Dr., Lothringer Strasse 29, W-2800 Bremen, (DE)

LEGAL REPRESENTATIVE:

Muller-Bore & Partner Patentanwalte (100651), Isartorplatz 6 Postfach 26
02 47, W-8000 Munchen 2, (DE)

PATENT (CC, No, Kind, Date): EP 398024 A1 901122 (Basic)
EP 398024 B1 930224

APPLICATION (CC, No, Date): EP 90107187 900314;

PRIORITY (CC, No, Date): DE 3912792 890419

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-049/02; A61K-047/48; A61K-049/00;
A61K-043/00;

ABSTRACT EP 398024 A1 (Translated)

The invention relates to conjugates consisting of

- a) at least one polyalcohol or a derivatised polyalcohol,
- b) at least one active agent,
- c) at least one linker and
- d) a protein, characterised in that the polyalcohol(s) or the derivatised polyalcohol(s) are polyalcohols or derivatised polyalcohols which are not recognised as foreign by the defence system of an organism, and the protein is a protein which is not recognised as foreign by the defence system of an organism and can be taken up specifically or non-specifically by the tumour. These conjugates are suitable, on the one hand, for making possible a very sensitive nuclear medical diagnosis of tumours and, on the other hand, for example for making available new tumour diagnosis methods in X-ray diagnosis, computed tomography, MR imaging, electron spin resonance spectroscopy or electron microscopy.

TRANSLATED ABSTRACT WORD COUNT: 138

ABSTRACT EP 398024 A1

Die Erfindung betrifft Konjugate, bestehend aus

- a) mindestens einem Polyalkohol oder einem derivatisierten Polyalkohol,
- b) mindestens einem aktiven Agens,
- c) mindestens einem Linker und
- d) einem Protein, dadurch gekennzeichnet, das der oder die Polyalkohole oder der oder die derivatisierten Polyalkohole vom Abwehrsystem eines Organismus nicht als körperfremd erkannte Polyalkohole oder derivatisierte Polyalkohole sind und das Protein ein vom Tumor spezifisch oder unspezifisch aufnehmbares, vom Abwehrsystem eines Organismus nicht als körperfremd erkanntes Protein ist. Diese Konjugate sind dazu geeignet, zum einen eine sehr empfindliche nuklearmedizinische Tumordiagnostik zu ermöglichen und zum anderen beispielsweise in der Röntgendiagnostik, Computertomographie, Kernspintomographie, Electron-Spin-Resonance-Spektroskopie, oder Elektronenmikroskopie auch neue Tumorerkennungsverfahren zu bieten.

ABSTRACT WORD COUNT: 110

LANGUAGE (Publication,Procedural,Application): German; German; German

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1584
CLAIMS B	(German)	EPBBF1	1377
CLAIMS B	(French)	EPBBF1	1705
SPEC B	(German)	EPBBF1	5404

DIALOG

Publication Date: January 16, 1986 (19860116)

FULL TEXT: 952 lines

ABSTRACT

An in vitro diagnostic method for detecting the presence in a patient of cancer cells or other cells producing mucin antigens comprises the step of testing a sample of a physiological fluid, particularly a sample of blood, blood serum or blood plasma, taken from the patient to detect the presence of small intestine mucin antigen (SIMA) and/or large intestine mucin antigen (LIMA) in the sample. An in vitro diagnostic kit is also disclosed.

16/3,AB/7 (Item 1 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2001 The Dialog Corp. All rts. reserv.

01963187

Utility

KIT OR SYSTEM FOR DETECTING SIMA AND/OR LIMA ANTIGENS IN PHYSIOLOGICAL FLUID

PATENT NO.: 5,008,184

ISSUED: April 16, 1991 (19910416)

INVENTOR(s): Linnane, Anthony W., Camberwell, AU (Australia)

ASSIGNEE(s): Mucan Diagnostics Pty Ltd , (A Non-U.S. Company or Corporation), Victoria, AU (Australia)
[Assignee Code(s): 20266]

EXTRA INFO: Assignment transaction [Reassigned], recorded May 25, 1994 (19940525)

APPL. NO.: 7-270,765

FILED: November 14, 1988 (19881114)

PRIORITY: PG5672, AU (Australia), June 25, 1984 (19840625)

This is a division of application Ser. No. 06-860,223, filed as PCT AU85-00136 on Jan. 21, 1985, published as WO86-00414 on Jun. 16, 1986, now U.S. Pat. No. 4,818,682.

FULL TEXT: 929 lines

ABSTRACT

This invention involves a kit or system for detecting SIMA and/or LIMA antigens in a physiological fluid.

?

DIALOG

mucus-secreting organs such as respiratory, genitourinary tracts, salivary and mammary glands did not show any reactivity to 7E6A5. These findings indicate that the antigen recognized by 7E6A5 is shared by the goblet cells of both the small and large intestines and is unique to them. The **monoclonal antibody** may be useful in the study of function of mucus-secreting goblet cells and may represent an important tool in the evaluation of diseases such as ulcerative colitis, colon cancer, and **intestinal metaplasia** in gastric mucosa that are associated with quantitative changes in goblet cell numbers or with qualitative differences in mucin secretion.

60/3,AB/6 (Item 1 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12530625 BIOSIS NO.: 200000284127

Prevalence of mAbDAS-1 positivity in biopsies from the esophagogastric junction.

AUTHOR: Wolf Claudi; Seldenrijk Cornelis A; **Das Kiron M** ; Timmer Robin;
Breumelhof Ronald; Smout Andre J; Amenta Peter S; Griffel Louis H

AUTHOR ADDRESS: (a)St Antonius Hosp Nieuwegein, Nieuwegein**Netherlands

JOURNAL: Gastroenterology 118 (4 Suppl. 2 Part 2):pAGA A1324-AGA A1325

April, 2000

MEDIUM: print.

CONFERENCE/MEETING: 101st Annual Meeting of the American
Gastroenterological Association and the Digestive Disease Week. San Diego,
California, USA May 21-24, 2000

SPONSOR: American Gastroenterological Association

ISSN: 0016-5085

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English

2000

60/3,AB/7 (Item 2 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12504662 BIOSIS NO.: 200000258164

Gastric intestinal metaplasia with colonic phenotype, as detected by a novel biomarker, mAbDAS-1, is highly associated with gastric carcinoma.

AUTHOR: **Das Kiron M** (a); Slate Jason A; Ramsundar Laura; Amenta Peter S;

Prasad Saket; Yokota Kinichi; Tanabe Hiroki; Sato Tomonobu; Kohgo Yutaka

AUTHOR ADDRESS: (a)UMDNJ/Robert Wood Johnson Med Sch, New Brunswick, NJ**
USA

JOURNAL: Gastroenterology 118 (4 Suppl. 2 Part 1):pA273 April, 2000

MEDIUM: print.

CONFERENCE/MEETING: 101st Annual Meeting of the American
Gastroenterological Association and the Digestive Disease Week. San Diego,
California, USA May 21-24, 2000

SPONSOR: American Gastroenterological Association

ISSN: 0016-5085

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English

2000

60/3,AB/8 (Item 3 from file: 5)

DIALOG

and tumor cells, and reactive with cancer cells from more than one organ but substantially not reactive with normal cells, and a process for production thereof; and a hybridoma cell line used to produce the above-mentioned monoclonal antibody, and a process for production thereof.

ABSTRACT WORD COUNT: 82

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	144
CLAIMS B	(German)	EPBBF1	130
CLAIMS B	(French)	EPBBF1	153
SPEC B	(English)	EPBBF1	3479
Total word count - document A			0
Total word count - document B			3906
Total word count - documents A + B			3906

51/3,AB/16 (Item 4 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00780421

13 HUMAN COLON AND COLON CANCER ASSOCIATED PROTEINS
13 PROTEINES ASSOCIEES AU CANCER DU COLON ET AU COLON HUMAIN

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

BIRSE Charles E, 13822 Saddleview Drive, North Potomac, MD 20878, US, US
(Residence), GB (Nationality), (Designated only for: US)
ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200112781 A1 20010222 (WO 0112781)
Application: WO 2000US22157 20000811 (PCT/WO US0022157)
Priority Application: US 99148680 19990813

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 114826

English Abstract

This invention relates to newly identified colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon cancer antigens", and the use of such colon antigens for detecting disorders of the gastrointestinal system, particularly the presence of colon cancer and colon cancer metastases. This invention relates to colon cancer antigens as well as vectors, host

DIALOG

en particulier un echantillon de sang, de serum sanguin ou de plasma sanguin, preleve chez le patient afin de detecter la presence dans l'echantillon d'un antigene mucine de l'intestin grele (SIMA) et/ou d'un antigene de mucine du gros intestin (LIMA). Est egalement decrit un kit de diagnostic in vitro.

41/3,AB/9 (Item 1 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

01756561

Utility

IN VITRO DETECTION OF GASTROINTESTINAL CANCER
[TESTING PHYSIOLOGICAL FLUID FOR SMALL OR LARGE INTTESTINE MUCIN ANTIGEN]

PATENT NO.: 4,818,682
ISSUED: April 04, 1989 (19890404)
INVENTOR(s): Linnane, Anthony W., Camberwell, AU (Australia)
ASSIGNEE(s): Mucan Diagnostics Pty Ltd , (A Non-U.S. Company or Corporation), Victoria, AU (Australia)
[Assignee Code(s): 20266]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 25, 1994 (19940525)
APPL. NO.: 6-860,223
FILED: April 24, 1986 (19860424)
PRIORITY: PG5672, AU (Australia), June 25, 1984 (19840625)
PCT: PCT-AU85-00136 (WO 85AU136)
Section 371 Date: April 24, 1986 (19860424)
Section 102(e) Date: April 24, 1986 (19860424)
Filing Date: June 21, 1985 (19850621)
Publication Number: WO86-00414 (WO 86414)
Publication Date: January 16, 1986 (19860116)

FULL TEXT: 952 lines

ABSTRACT

An in vitro diagnostic method for detecting the presence in a patient of cancer cells or other cells producing mucin antigens comprises the step of testing a sample of a physiological fluid, particularly a sample of blood, blood serum or blood plasma, taken from the patient to detect the presence of small intestine mucin antigen (SIMA) and/or large intestine mucin antigen (LIMA) in the sample. An in vitro diagnostic kit is also disclosed.

41/3,AB/10 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2001 The Dialog Corp. All rts. reserv.

01963187

Utility

KIT OR SYSTEM FOR DETECTING SIMA AND/OR LIMA ANTIGENS IN PHYSIOLOGICAL FLUID

PATENT NO.: 5,008,184
ISSUED: April 16, 1991 (19910416)
INVENTOR(s): Linnane, Anthony W., Camberwell, AU (Australia)
ASSIGNEE(s): Mucan Diagnostics Pty Ltd , (A Non-U.S. Company or Corporation), Victoria, AU (Australia)

French Abstract

La presente invention porte sur un marqueur (proteine) utilise dans le traitement et le diagnostic des cancers, ainsi que sur l'utilisation de cette proteine, d'un fragment immunogene ou d'un analogue de celle-ci, ainsi que sur des agents de liaison specifiques contre celle-ci, sur l'utilisation de cette proteine dans la fabrication de medicaments et sur des kits de test et des procedes de test. L'invention porte egalement sur une sequence nucleotidique codant ladite proteine.

33/3,AB/31 (Item 28 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00340887

**CANCER IMMUNOTHERAPY WITH ANTIBODIES TO CANCER PROCOAGULANT
IMMUNOTHERAPIE CONTRE LE CANCER REALISEE AVEC DES ANTICORPS DIRIGES CONTRE
LE PROFACTEUR DE COAGULATION DU CANCER (PC)**

Patent Applicant/Assignee:

UNIVERSITY RESEARCH CORPORATION

Inventor(s):

GORDON Stuart G

Patent and Priority Information (Country, Number, Date):

Patent: WO 9401536 A1 19940120

Application: WO 92US5726 19920707 (PCT/WO US9205726)

Priority Application: WO 92US5726 19920707

Designated States: AU CA ES JP AT BE CH DE DK ES FR GB GR IT LU MC NL SE

Publication Language: English

Fulltext Word Count: 11075

English Abstract

This invention describes a method of tumor prevention using cancer procoagulant (CP) antigen and antibodies in immunization procedures. CP is also used in a method to specifically destroy malignant cells. In addition, a method is described herein for producing a stable hybridoma for the production of **monoclonal antibodies** to CP.

Japanese Abstract

Procede de prevention des tumeurs dans lequel on utilise l'antigene et des anticorps diriges contre le profacteur de coagulation du cancer (PC) dans des procedures d'immunisation. On utilise egalement le PC dans un procede permettant de detruire de maniere specifique des cellules malignes. Cette invention concerne egalement un procede de production d'un hybridome stable utile pour produire des anticorps monoclonaux diriges contre le profacteur de coagulation du cancer.

33/3,AB/49 (Item 14 from file: 654)

DIALOG(R) File 654:US Pat.Full.

(c) format only 2001 The Dialog Corp. All rts. reserv.

03151324

Utility

**COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS
OF USING THE SAME**

PATENT NO.: 6,087,109

ISSUED: July 11, 2000 (20000711)

INVENTOR(s): Waldman, Scott A., Ardmore, PA (Pennsylvania), US (United States of America)

DIALOG

Total word count - document A 0
 Total word count - document B 10070
 Total word count - documents A + B 10070

28/3,AB/62 (Item 55 from file: 348)
 DIALOG(R)File 348:EUROPEAN PATENTS
 (c) 2001 European Patent Office. All rts. reserv.

00234410

PROCESS AND COMPOSITION FOR TREATMENT OF CANCER AND NON-MALIGNANT TUMORS.
 VERFAHREN UND ZUSAMMENSETZUNG ZUR BEHANDLUNG VON KREBS UND NICHTMALIGNEN
 TUMOREN.

PROCEDE ET COMPOSITION POUR LE TRAITEMENT DU CANCER ET DE TUMEURS NON
 MALIGNES.

PATENT ASSIGNEE:

Landucci, Gary R, (1473140), 216 Saybrook Court, Costa Mesa, California
 92627, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

Mariani, Toni N., (1473150), 1924 East River Terrace, Minneapolis,
 Minnesota 55414, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

Landucci, Gary R, 216 Saybrook Court, Costa Mesa, California 92627, (US)

Mariani, Toni N., 1924 East River Terrace, Minneapolis, Minnesota 55414,
 (US)

LEGAL REPRESENTATIVE:

Bannerman, David Gardner et al (28001), Withers & Rogers 4 Dyer's
 Buildings Holborn, London, EC1N 2JT, (GB)

PATENT (CC, No, Kind, Date): EP 227809 A1 870708 (Basic)

EP 227809 A1 871209

EP 227809 B1 920923

WO 8700054 870115

APPLICATION (CC, No, Date): EP 86904562 860626; WO 86US1348 860626

PRIORITY (CC, No, Date): US 750091 850628

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-037/66; A61K-039/395; A61K-035/12;

C12N-001/36; C12N-001/38;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	452
CLAIMS B	(German)	EPBBF1	396
CLAIMS B	(French)	EPBBF1	532
SPEC B	(English)	EPBBF1	8951

Total word count - document A 0

Total word count - document B 10331

Total word count - documents A + B 10331

?